Zacks: Pharming Group (NASDAQ:PHGUF) Receives Average Recommendation of “Strong Buy” from Analysts
Shares of Pharming Group (NASDAQ:PHGUF) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Zacks has also given Pharming Group an industry rank of 105 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised Pharming Group from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.
Shares of Pharming Group (NASDAQ:PHGUF) traded up 4.00% during midday trading on Wednesday, hitting $0.26. The company had a trading volume of 500 shares. The firm’s market capitalization is $107.26 million. Pharming Group has a 12 month low of $0.17 and a 12 month high of $0.35. The company has a 50-day moving average of $0.00 and a 200 day moving average of $0.00.
About Pharming Group
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.